Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Avid Bioservices Inc - SIC # 2835 - IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
CDMO
Nasdaq
2835
https://avidbio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Avid Bioservices Inc
Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q
- Mar 20th, 2024 11:00 am
Avid Bioservices Inc (CDMO) Releases Preliminary Q3 Financial Results
- Mar 11th, 2024 1:01 am
Avid Bioservices Announces Pricing of Private Placement of Convertible Notes
- Mar 7th, 2024 4:58 am
Avid Bioservices Announces Proposed Private Placement of Convertible Notes
- Mar 6th, 2024 9:32 pm
Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024
- Mar 6th, 2024 9:31 pm
Avid Bioservices (CDMO) Declined in 2023
- Jan 30th, 2024 6:11 am
Insider Stock Buying Reaches US$527.5k On Avid Bioservices
- Jan 12th, 2024 10:33 am
Director Richard Hancock's Strategic 23,000 Share Purchase in Avid Bioservices Inc
- Dec 19th, 2023 10:01 am
Avid Bioservices, Inc. (NASDAQ:CDMO) Q2 2024 Earnings Call Transcript
- Dec 8th, 2023 1:15 pm
Avid Bioservices Inc (CDMO) Adjusts Fiscal 2024 Revenue Guidance Amidst Second Quarter Challenges
- Dec 7th, 2023 10:51 pm
Avid Bioservices (CDMO) Reports Q2 Loss, Lags Revenue Estimates
- Dec 7th, 2023 10:40 pm
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2023
- Dec 7th, 2023 9:05 pm
Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
- Dec 1st, 2023 11:16 pm
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2024 After Market Close on December 7, 2023
- Nov 30th, 2023 9:05 pm
Down -22.27% in 4 Weeks, Here's Why Avid Bioservices (CDMO) Looks Ripe for a Turnaround
- Nov 28th, 2023 2:35 pm
Avid Bioservices (CDMO) Moves 9.0% Higher: Will This Strength Last?
- Nov 15th, 2023 9:02 am
Aclaris (ACRS) Lead Drug Fails Rheumatoid Arthritis Study
- Nov 14th, 2023 3:57 pm
Avid Bioservices (NASDAQ:CDMO investor one-year losses grow to 67% as the stock sheds US$88m this past week
- Nov 11th, 2023 12:23 pm
Jazz (JAZZ) Lags Q3 Earnings, Beats Sales, Raises '23 View
- Nov 9th, 2023 6:20 pm
Avid Bioservices Partners With California Institute for Regenerative Medicine (CIRM) to Provide CDMO Services for Cell and Gene Therapy (CGT) Programs
- Nov 8th, 2023 1:05 pm
Scroll